China, Nov. 16 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A prospective study of Befotertinib adjuvant therapy in patients with postoperative MRD-positive non-small cell lung cancer in Stage IA2-IB with high risk factors'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600136666

Registration Time: 2026/11/13

Type: Interventional study

Primary Sponsor: Shanghai Cancer Center Fudan University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=240002

Published by HT Digital Content Services with permission from Health Daily Digest....